Ngl Fine-chem Ltd. · NSE:NGLFINE
Ngl Fine-chem — Q1 FY2025 Earnings Presentation
16 slides from Ngl Fine-chem's earnings presentation, Aug 20, 2024
Slide 1: Cover letter to stock exchanges for Investor Presentation
Regd. Office 301, E – Square, Subhash Road, Vile Parle East, Mumbai 400057 Maharashtra, India. Tel.: (+91 22) 40842222, Fax: (+91 22) 2610 8030, Email: info@nglfinechem.com CIN L24110MH1981PLC025884,Website www.nglfinechem.com August 20, 2024 To, Listing Department, Listing Department, The BSE Limit
Slide 2: NGL Fine-Chem Limited Investor Presentation Q1FY25
NGL Fine-Chem Limited IN V ES TO R P RE SE N TAT ION Q1F Y2 5
Slide 3: Disclaimer
Disclaimer This investor presentation has been prepared by NGL Fine-Chem Limited and does not constitute a prospectus or placement memorandum or an offer to acquire any securities. This presentation or any other documentation or information (or any part thereof) delivered or supplied should not be d
Slide 4: Inside This Presentation
Inside Pg. No. Pg. No. This Presentation 04 08 Q1FY25 Over view, Highlights Key Strengths and Strategy Pg. No. 13 Historical Financial Performance
Slide 5: Q1FY25 Highlights
01 Q1FY25 Highlights 05 M A N AG E M E N T C O M M E N TA R Y 06 Q UA R T E R LY O PE R AT IO N A L M E T R IC S 07 S U M M A R Y O F P RO FI T A N D LO S S S TAT E M E N T
Slide 6: Management Commentary
MANAGEMENT COMMENTARY Dear Shareholders, f a ce ch al le n g es w ith el e va te d l og ist ics cos ts, I a m pl ea se d t o pr e se n t o ur pe r f or m an ce f or p ar t icu la r ly a f f ect in g o u r e xp or ts t o th e L ATAM Q 1 FY 2 5 . Th e s al es h a ve gr o wn on a Y OY ba si s a n d Eu
Slide 7: Operational Metrics
Operational Metrics SEGMENTAL REVENUE MIX PRODUCT CONCENTRATION PARTICULARS Q1FY24 Q4FY24 Q1FY25 PARTICULARS Q1FY24 Q4FY24 Q1FY25 ANIMAL API 87% 90% 90% TOP 3 PRODUCTS 34% 34% 32% HUMAN API 3% 3% 5% TOP 5 PRODUCTS 50% 49% 47% INTERMEDIATES 7% 3% 3% TOP 10 PRODUCTS 73% 72% 71% FORMULATIONS 4% 4% 2% G
Slide 8: Summary of Profit and Loss Statement
Summary of Profit and Loss Statement ₹ I N CR O RES PA RT I CULA RS Q1FY24 Q4FY24 Q1FY25 Q-o-Q Y-o-Y REVENUE FROM OPERATIONS 71.04 99.76 90.75 -9.03% 27.75% OTHER INCOME 3.32 3.68 5.88 59.90% 77.16% TOTAL INCOME 74.36 103.44 96.64 -6.58% 29.95% TOTAL OPERATING EXPENSES 61.18 83.94 81.40 -3.02% 33.06
Slide 9: Overview, Strengths and Strategy
02 Overview, Strengths and Strategy 09 L E A D I N G A N IM A L H E A LT H C O M PA N Y 10 L E A D E R S H I P IN V E T E R IN A RY A P I S E G M E N T 11 S TAT E - O F - T H E - A R T M A N U FA C T U R I N G C A PA BI L I T I E S 12 S T R AT E G Y F O R N E X T L E G O F G R O W T H
Slide 10: Leading Animal Health Company
Leading Animal Health Company COMPREHENSIVE MARKET MANUFACTURING LARGE GLOBAL LONG STANDING PRODUCT LEADERSHIP EXCELLENCE PRESENCE CUSTOMER PORTFOLIO IN VETERINARY API RELATIONSHIPS • 32 APIs (30 Veterinary • Leadership in top • 3 state of the art • 50+ countries across • ~400 customers APIs, 2 Huma
Slide 11: Leadership in Veterinary API Segment
Leadership in Veterinary API Segment REVENUE FROM VETERINARY CUSTOMER & PRODUCT Strong controls of processes with 95% in-house manufacturing and API SEGMENT ( ₹ IN C RO RE S) 22% CAGR CONCENTRATION (OF SALES FY24) backward integrated facilities leading to cost competitiveness FY24 300 CUSTOMER PRODU
Slide 12: State-of-the-art Manufacturing Capabilities
State-of-the-art Manufacturing Capabilities HIGHLIGHTS 3 manufacturing facilities located at Tarapur & Navi 10,000 m 2 102 m 3 194 m 3 AREA OF GLASS-LINED STAINLESS STEEL Mumbai, Maharashtra, MANUFACTURING REACTORS REACTORS designed to meet the FACILITIES requirements of regulatory agencies and are
Slide 13: Strategy for next leg of growth
Strategy for next leg of growth BROWNFIELD EXPANSIO N • Completed expansion in ONGOING INITIATIVES subsidiary Macrotech TO INCREASE • Additional capacities of a CAPACITIES TO MEET intermediates GROWING DEMAND • Commercial production started GREENFIELD EXPANSIO N AT TARAP UR • 50% capacity expansion
Slide 14: Historical Financial Performance
03 Historical Financial Performance 14 R O B US T FI N A N C I A L PE R F O R M A N C E
Slide 15: Robust Financial Performance
Robust Financial Performance REVENUE EBITDA PAT (₹ I N C RORES) (₹ I N C RORES) (₹ I N C RORES) FY24 339 FY24 53 FY24 41 FY23 278 FY23 34 FY23 21 FY22 318 FY22 68 FY22 50 FY21 258 FY21 80 FY21 57 FY20 152 FY20 19 FY20 8 0 50 10 0 15 0 20 0 25 0 30 0 35 0 40 0 0 10 20 30 40 50 60 70 80 90 0 10 20 30
Slide 16: Thank You
FOR ANY FURTHER INFORMATION, PLEASE CONTACT Thank You Pallavi Pednekar Abhishek Mehra NG L F I NE - C H E M T I L A D VI S O R S P R I V A T E L I MI TE D L I MI TED cs@nglfinechem.com abhishek@theinvestmentlab.in +91 22 40842222 +91 95588 14500 Corporate Office 3 01 , E- s q u a r e, S u b h a sh R